Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy

Recently, immunotherapeutic drugs, including PD-1 inhibitors (nivolumab, pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab), and CTLA4 inhibitors (ipiliumumab), have emerged as important additions to the armamentarium against certain malignancies and have been incorporated into therapeutic pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Palla, Amruth R., Kennedy, Devin, Mosharraf, Hossain, Doll, Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126613/
https://www.ncbi.nlm.nih.gov/pubmed/27920704
http://dx.doi.org/10.1159/000452296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126613/
https://www.ncbi.nlm.nih.gov/pubmed/27920704
http://dx.doi.org/10.1159/000452296

Ejemplares similares